echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Eli Lilly and Evotec sign $1 billion partnership to focus on kidney disease and diabetes

    Eli Lilly and Evotec sign $1 billion partnership to focus on kidney disease and diabetes

    • Last Update: 2022-02-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Eli Lilly and Evotec SE jointly announced that the two companies have entered into a drug discovery collaboration in the field of metabolic diseases, focusing on kidney disease and diabetes


    The collaboration will leverage Evotec's experience and expertise in metabolic disease, as well as its unique and extensive renal disease patient database, integrated data-driven drug discovery and development platform, to identify and validate promising new targets for therapeutic intervention


    Evotec will be responsible for discovering potential drug candidates for diabetes and chronic kidney disease from targets identified by Eli Lilly or Evotec


    The partnership will initially run for three years


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.